Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the Europa study)
| Other(s) | ||
|---|---|---|
Baubinienė, Alla | Atstovas / Originator | Klaipėdos apskrities administracija |
Berūkštis, Egidijus | Atstovas / Originator | Vilniaus universitetas |
Grigonienė, Lina | Atstovas / Originator | Vilniaus universitetinė Antakalnio ligoninė |
Kibarskis, Aleksandras | Atstovas / Originator | Vilniaus universitetas |
Atstovas / Originator | ||
Marcinkus, Romualdas | Atstovas / Originator | Kauno medicinos universiteto Kardiologijos institutas |
Milvidaitė, Irena | Atstovas / Originator | Lietuvos sveikatos mokslų universitetas |
Vasiliauskas, Donatas Antanas | Atstovas / Originator | Kauno medicinos universiteto Kardiologijos institutas |
| Date Issued |
|---|
2003 |
Background. Treatment with angiotensin-converting-enzyme (ACE) inhibitors reduces the rate of cardiovascular events among patients with left-ventricular dysfunction and those at high risk of such events. We assessed whether the ACE inhibitor perindopril reduced cardiovascular risk in a low-risk population with stable coronary heart disease and no apparent heart failure. Methods We recruited patients from October, 1997, to June, 2000. 13 655 patients were registered with previous myocardial infarction (64%), angiographic evidence of coronary artery disease (61%), coronary revascularisation (55%), or a positive stress test only (5%). After a run-in period of 4 weeks, in which all patients received perindopril, 12 218 patients were randomly assigned perindopril 8 mg once daily (n=6110), or matching placebo (n=6108). The mean follow-up was 4.2 years, and the primary endpoint was cardiovascular death, myocardial infarction, or cardiac arrest. Analysis was by intention to treat...